Helsinki, Finland — 24.10.2025 — Lynsight is proud to announce a strategic partnership with New Day Diagnostics, a leading innovator in diagnostic solutions, to initiate clinical studies and accelerate market access for DiagMMR in the United States.
This collaboration marks a significant milestone in Lynsight’s mission to expand access to advanced diagnostic technologies and improve early detection of hereditary cancer syndromes. It also signals the beginning of a broader commercial alliance, combining clinical validation with infrastructure and expertise to scale DiagMMR across the United States.
DiagMMR is Lynsight’s proprietary diagnostic solution designed to identify mismatch repair deficiencies, the key biomarker in Lynch syndrome. Through this partnership, Lynsight and New Day Diagnostics will jointly conduct clinical studies across selected US sites, ensuring rigorous validation and regulatory alignment to drive US market entry.
“Partnering with New Day Diagnostics gives us a powerful launchpad for DiagMMR in the US,” said Niklas Lahti, Chief Executive Officer at Lynsight. “Their strong operational expertise, market knowledge, and shared commitment to quality and growth make them an ideal partner for us. Together with our clinical network, we are building momentum for an impactful and scalable launch.”
The collaboration will leverage New Day Diagnostics’ clinical research infrastructure and Lynsight’s scientific expertise to generate robust data supporting DiagMMR’s efficacy and reliability in joint effort to obtain marketing authorization through the FDA. The studies are expected to begin in early 2026 with top-tier US healthcare institutions, recognized for translational research, shaping national standards in diagnostics and care, and delivering clinical excellence.
”Lynsight’s DiagMMR is a ground-breaking tool that will advance the global fight against cancer,” said Eric Mayer, New Day Diagnostics President and CEO. “We are excited to partner with Lynsight to bring this technology to the United States, complementing New Day’s experience in colorectal cancer early detection while driving the shared mission to empower individuals for a healthier future through novel, widely-accessible diagnostics.”
This partnership underscores Lynsight’s commitment to international expansion and innovation in
preventive healthcare.
About Lynch Syndrome
Lynch syndrome is the leading cause of hereditary cancers, encompassing a wide range of tumors, with colorectal and endometrial cancers being the most common. It is estimated that 1 in 300 people worldwide are affected by Lynch syndrome, with the majority still undiagnosed. This means millions of individuals are unknowingly at a significantly high lifetime risk for cancer.
About New Day Diagnostics
New Day Diagnostics is a health innovation company based in Knoxville, Tennessee, committed to making diagnostic testing more accessible, efficient and patient-friendly. Their mission is to make health information more accessible, accelerating the path from discovery to diagnosis when it is most critical to improving patient care and outcomes.
About Lynsight
For over a decade, Lynsight has been dedicated to advancing Lynch syndrome research with a commitment to discovering innovative methods for cancer prevention. Based in Helsinki, Finland, Lynsight provides reliable Lynch syndrome diagnostics to empower families and healthcare professionals to make better informed decisions for cancer prevention, so healthcare providers and families can focus on the path instead of the problem.
